Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
Advances in Cardiometabolic Health
share announcement

Advances in Cardiometabolic Health

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 3645

Special Issue Editors

Dr. Pamela Senesi

E-Mail Website
Guest Editor
1. Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20131 Milan, Italy
2. Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS Multimedica, 20099 Sesto San Giovanni and Ospedale San Giuseppe, Milan, MI, Italy
Interests: insulin signalling; nutrition; obesity; type 2 diabetes; cardiometabolic disorders; physical exercise; organokines
Special Issues, Collections and Topics in MDPI journals
Dr. Anna Ferrulli

E-Mail Website
Guest Editor
1. Deptartment of Biomedical Sciences for Health, Università degli Studi di Milano, 20131 Milano, MI, Italy
2. Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS Multimedica, 20099 Sesto San Giovanni and Ospedale San Giuseppe, Milan, MI, Italy
Interests: obesity; type 2 diabetes; metabolic diseases; obesity treatment; neuromodulation; eating behaviour; cardiovascular diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Obesity represents a major global health concern in relation to cardiometabolic disorders. Currently, the worldwide obesity rate (more than 1 billion people) has nearly doubled since 1980, and one in five women and one in seven men will have obesity by 2030.

Growing evidence indicates that personalized diets, according to the individual's genotype, age and/or enterotype, represent the optimal therapeutic strategy to counteract obesity. In addition, training personalized programs are needed to improve nutritional strategies.

However, therapeutic lifestyle changes are often inadequate.

Recently, certain pharmacological therapy as an adjunct to lifestyle modifications has been approved. In addition, different type 2 diabetes drugs, GLP-1 agonists and SGLT-2 inhibitors, lead to weight loss and protect cardiac function. Moreover, bariatric surgery is an efficacy strategy to reduce obesity-related risks in severe obesity.

Finally, different innovative approaches, as neuromodulation or artificial intelligence (AI)-based platforms, are testing to improve cardiometabolic health.

In this Special Issue, we will focus on novel strategies to maintain cardiometabolic health through the development of personalized treatments.

We will also investigate the interplay between nutrient intake, dietary pattern consumption, exercise and drugs with cellular mechanisms that affect appetite, thermogenesis and metabolism.

Reviews, original research articles and communications are welcome.

Dr. Pamela Senesi
Dr. Anna Ferrulli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • obesity
  • cardiovascular diseases
  • biomarkers
  • lifestyle interventions
  • personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 764 KiB  
Article
Increased Cardiometabolic Risk in Men with Hypoprolactinemia: A Pilot Study
by Robert Krysiak, Karolina Kowalcze, Witold Szkróbka and Bogusław Okopień
Biomolecules 2024, 14(10), 1335; https://doi.org/10.3390/biom14101335 - 20 Oct 2024
Viewed by 1628
Abstract
Low prolactin levels in men predispose them to mood disturbances, sexual dysfunction, and diabetes. The purpose of the current study was to assess cardiometabolic risk in males with hypoprolactinemia. This prospective study included three age-matched groups of young and middle-aged men: individuals with [...] Read more.
Low prolactin levels in men predispose them to mood disturbances, sexual dysfunction, and diabetes. The purpose of the current study was to assess cardiometabolic risk in males with hypoprolactinemia. This prospective study included three age-matched groups of young and middle-aged men: individuals with cabergoline-induced hypoprolactinemia (n = 15), cabergoline-treated subjects with prolactin levels within the reference range (n = 20), and untreated men with normal prolactin levels (n = 31). In men with hypoprolactinemia, the cabergoline dose was reduced in order to normalize prolactin concentration. Anthropometric parameters, blood pressure, QRISK3 score; plasma concentrations of prolactin, glucose, insulin, lipids, uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine, and testosterone; whole-blood levels of glycated hemoglobin (HbA1C); urinary albumin-to-creatinine ratio (UACR); and carotid intima–media thickness were assessed at baseline and six months later. Men with hypoprolactinemia were characterized by higher body mass index, fat content, waist circumference, systolic blood pressure, fasting and 2 h post-load glucose, HbA1C, HOMA1-IR, uric acid, hsCRP, fibrinogen, homocysteine, and UACR; by lower HDL cholesterol and testosterone; by greater intima–media thickness; and by a higher QRISK3 score than their peers with normal prolactin levels. There were no statistically significant differences in the measured parameters between both groups of men with normal prolactin levels. Normalization of prolactin concentration was accompanied by normalization of biochemical variables, systolic blood pressure, and QRISK3 score. Although cabergoline dose reduction did not cause statistically significant changes in the remaining anthropometric parameters and intima–media thickness, six months later, they did not differ from those observed in the remaining study groups. Our findings suggest that iatrogenic hypoprolactinemia is associated with increased cardiometabolic risk, which is reversible and resolves after the normalization of prolactin levels. Full article
(This article belongs to the Special Issue Advances in Cardiometabolic Health)
►▼ Show Figures

Figure 1

18 pages, 1006 KiB  
Article
Concentrations of Glypican-4, Irisin and Total Antioxidant Status in Women with Metabolic Syndrome: Influence of Physical Activity
by Teresa Grzelak, Marcelina Sperling, Marta Pelczyńska, Aniceta Ada Mikulska-Sauermann, Paweł Bogdański, Krystyna Czyżewska and Edyta Mądry
Biomolecules 2024, 14(7), 768; https://doi.org/10.3390/biom14070768 - 27 Jun 2024
Cited by 1 | Viewed by 1502
Abstract
Glypican-4 belongs to a group of poorly understood adipokines, with potential importance in people with metabolic syndrome, especially in groups of patients with glucose metabolism disorder. This study aimed to assess the effect of physical activity on serum glypican-4 and irisin levels and [...] Read more.
Glypican-4 belongs to a group of poorly understood adipokines, with potential importance in people with metabolic syndrome, especially in groups of patients with glucose metabolism disorder. This study aimed to assess the effect of physical activity on serum glypican-4 and irisin levels and total antioxidant status (TAS) in plasma and saliva in women with metabolic syndrome (MetS). Seventy-two Caucasian women aged 25–60 were included in the study (36 women with MetS and 36 women without MetS (control group, CONTR)). The glypican-4 and irisin concentrations, total antioxidant status, glycemia, lipid profile, anthropometric parameters, and blood pressure were analyzed before and after 28 days of controlled physical activity. Serum glypican-4 and plasma TAS levels were higher (p = 0.006 and p = 0.043, respectively) on the 28th day than on the first day of the study only in the CONTR group. In the MetS group, 28 days of physical activity caused a reduction in body fat mass (p = 0.049) without changes in glypican-4, irisin, or TAS levels. In both groups, glypican-4 levels correlated positively with irisin levels and negatively with Waist-Hip Ratio (WHR), while irisin levels correlated positively with High-Density Lipoprotein Cholesterol (HDL-C) levels and negatively with waist circumference (WC) and WHR values on the 28th day of the study. To summarize, a 28-day moderate training, accompanied by a reduction in body fat mass, stabilized glypican-4 levels and TAS in female patients with MetS. Full article
(This article belongs to the Special Issue Advances in Cardiometabolic Health)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop